For more information about products within the Pathway Portfolio, please click here for prescribing information
For more information about products within the Pathway Portfolio, please click here for prescribing information
Indicated for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.4
Assicco® is the only available brand of glycopyrronium bromide tablets1.
Assicco® could reduce the average ICS/ICB prescribing costs of glycopyrronium bromide tablets by an average of £131,000 per annum, saving up to £5.5 million annually across the NHS5*.
Indicated for Schizophrenia, Bipolar Disorder and as add-on treatment for Major Depressive Disorder6.
Biquelle® XL: the most complete range of quetiapine prolonged-released tablets, with a 600mg strength available1.
(Biquelle XL 600mg dose, is only available as a 30 day pack.)‡
Biquelle® XL could reduce the average ICS/ICB prescribing costs of quetiapine prolonged release tablets by an average of £223,173 per annum, saving up to £9.4 million annually across the NHS5*.
Indicated for symptomatic treatment of mild to moderately severe dementia of the Alzheimer type7.
Save 50% on your current galantamine prolonged-release prescribing costs by prescribing Gatalin® XL by brand1.
Gatalin® XL could reduce the average ICS/ICB prescribing costs of galantamine prolonged-release capsules by an average of £24,414 per annum, saving the NHS up to £1 million annually across the UK5*.
Indicated for treatment of Parkinson’s disease as monotherapy and use in combination with levodopa when the effect of levodopa wears off or becomes inconsistent8.
Save 50% on your current ropinirole prolonged-release prescribing costs by prescribing Repinex XL by brand1.
Repinex® XL could reduce the average ICS/ICB prescribing costs of ropinirole prolonged release tablets by an average of £47,599 per annum, saving up to £2 million annually across the NHS5*.
Indicated for the treatment of major depressive episodes (MDEs), prevention of recurrence of MDEs, generalised anxiety disorder, social anxiety disorder and panic disorder, with or without agoraphobia9.
Prescribing Vencarm® XL by brand remains the most cost-effective range of venlafaxine prolonged release capsules1.
Vencarm® XL could reduce the average ICS/ICB prescribing costs of venlafaxine prolonged release capsules by an average of £357,143 per annum, saving up to £15 million annually across the NHS5*.
*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 42 ICS/ICB’s
‡ Biquelle XL 600mg dose, is only available as a 30 day pack.
XLW1010311C3_OCT2024